HomeMarketsSharesOPKO Health, Inc.

Trade OPKO Health, Inc. - OPK CFD

1.2240+2.51%
The chart shows the OPK stock price data over the last 1 day, with a current price of 1.2240, a high of 1.206, and a low of 1.146.
Low: 1.146High: 1.206
Sellers:
0%
Buyers:
100%
Past performance is not a reliable indicator of future results
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.0180
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.021568 %
(-$4.31)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02157%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.000654 %
(-$0.13)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.00065%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity10
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close1.166
Open1.156
1-Year Change-38.71%
Day's Range1.146 - 1.206
OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company''s Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women''s health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services. The company''s Pharmaceutical segment offers Rayaldee for treatment for secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and associated obesity that is in Phase IIb trials; and hGH-CTP, a once-weekly human growth hormone injection that completed Phase III clinical trial in partnership with Pfizer, Inc. This segment develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins. It also specialty active pharmaceutical ingredients; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and imports, markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. In addition, the company operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida.

Latest shares articles

Camouflaged military armored vehicle displayed at a defense industry exhibition in front of a HENSOLDT booth
HENSOLDT stock forecast: FY2025 results and 2026 guidance
HENSOLDT (HAG) is a German defence electronics company; its shares have pulled back after FY2025 results showed €4.71bn order intake, €2,455m revenue and €89m net income, alongside 2026 guidance of €2,750m revenue and 18.5%–19% EBITDA margin.
8 minutes ago
Rheinmetall company logo displayed on the facade of a modern office building with glass windows
Rheinmetall stock forecast: Debt brake shift, €500bn fund
Rheinmetall (RHM) is a German defence group; in Feb 2026 it guided to €15–€16bn group revenue and up to €80bn orders, as Germany’s debt-brake debate and a €500bn fund remained in focus. Past performance is not a reliable indicator of future results. Explore third-party RHM price targets.
20 minutes ago
Siemens Energy flag on a pole
Siemens Energy stock forecast: €2bn share buyback plan
Siemens Energy is a German power and grid equipment company; on 3 March 2026 it announced a €2bn share buyback and raised mid-term targets after a capital markets day. Explore third-party ENR price targets and technical analysis. Past performance is not a reliable indicator of future results.
52 minutes ago
DTE logo displayed on a red corporate sign outside a modern office building
DTE stock forecast: Starlink satellite-to-mobile deal
Deutsche Telekom (DTE) is a European telecoms group; its 2025 results – revenue €119.08bn – and a Starlink satellite-to-mobile partnership announced in March 2026 remain key reference points. Past performance is not a reliable indicator of future results. Explore third-party DTE price targets.
15:30, 6 March 2026

Read our reviews to find out more about us

Read the feedback from our clients, whatever their experience level.
2025-07-01
V***** F******* N***** S****

Great customer service I got to say that. They helped get my account back very fast, after i logged myself out by losing my old email, it was so fast you wouldn’t believe it thank you once again.

2025-06-30
B******

Everything worked as expected from the 1 day. I didn’t have to search how to use the platform, it’s intuitive. The support chat was there when I had a tiny issue.

2025-06-27
G** G******

Capital.com has been great for both learning and trading. The app is clean, fast, and packed with useful tools. Customer support has been solid too. Definitely recommended for beginners and active traders alike.

2025-06-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-06-19
d*********

I would like to express a huge thank you to Evgeniya Logvinovich, customer service manager. For your attention and heartfelt attitude to your clients.❤️

2025-06-19
f*********

I am extremely happy with this broker. Great spreads, good selection of instruments, well coded toolbox.

2025-05-29
C*********

Love the TV integration. Makes traders life smooth and comfortable.

2025-05-24
R**************

I trade every day and Capital is my beloved home. I also create music and you can always feel when something has been created from the heart. Capital has soul!

2025-05-20
G****

I’d been paper trading for 2yrs now, went live and this platform is easy for beginners to understand and navigate all important tools to execute all that I learned. Earning now!

2025-04-29
d******

This application is perfect.. simple, easy to use, run smoothly and fast and it has an accurate graphics.. be careful to use only one credit card and one bank account to prevent any withdrawal problem.. overnight fees and spread variation will be repaid for you by the next month.. I used many application but this is the best one

2025-02-06
N***** B***

User friendly app & interface and good support team. Funds transfer ease & Leverage is an advantage but crypto is highly risky be responsible of your loss limits and risks appetite.

2025-06-29
p*******

Capital is really great to be used on start, also beginner friendly broker! Great costumer support and it is quick!

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

Join our community of traders worldwide
1. Create your account2. Make your first deposit3. Start trading